MedTrace Logo

Nephrologic Intervention in Patients Waiting for Cardiac Surgery

NCT02643745 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2021-01-11

No results posted yet for this study

Summary

Acute kidney injury (AKI) is a frequent complication after cardiac surgery. Its incidence ranges from 19 to 44% depending on the study and which definition is used: Acute Kidney Injury Network (AKIN) classification or RIFLE criteria (Risk, Injury, Failure, Loss, End-Stage Kidney Disease) based on serum creatinine and urine output.

AKI is associated with increased mortality, more complications, a longer stay in the intensive care unit and hospital, and increased health care costs. Moreover, the patients who require renal replacement therapy (RRT) have the highest mortality and complications1.The mortality risk in patients developing acute renal dysfunction after cardiac surgery increases by approximately 40%, while the overall mortality rate after cardiac surgery ranges between 2% and 8%.

There are some well-known risk factors associated with AKI, including baseline patient characteristics (age and comorbidities), need of perioperative blood transfusion or presence of previous chronic kidney disease. The main objective of this study is to evaluate if a nephrologist management and control of potential risk factors of renal disease can be used to prevent AKI, thereby minimizing the risk of need RRT, reducing costs and improving survival in this patients.

Conditions

Interventions

PROCEDURE

Nephrology Intervention

1. pre-operative study: * Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added. * Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc. 2. optimise the patient' s overall condition with a pre-operative strategy: * Obesity control * Control protein, caloric, salt intake * Stop smoking * Good glycemic control * Start ACEI/ARA II if there is proteinuria * Start additional antihypertensive drug if required * Start hypolipemic treatment if required * Start hyperuricemia treatment if required * Start AAS, clopidogrel if it is necessary (prophylaxis) * Phosphate control * Anemia control * Metabolic acidosis correction

Sponsors & Collaborators

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Nuria Montero, MD · Hospital Universitari de Bellvitge

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02643745 on ClinicalTrials.gov